Scholarlink

Purpose <p>CRS-HIPEC serves as the primary treatment for peritoneal cancers. Although CRS-HIPEC frequently yields positive outcomes, some patients may experience a swift recurrence of cancer. Consequently, a technique to detect any remaining viable tumor cells post-treatment would be advantageous. We propose to explore the feasibility of employing flow cytometry to differentiate viable tumor cells following CRS-HIPEC treatment.</p> Patients and methods <p>During the CRS-HIPEC procedure, peritoneal fluid was collected at two distinct time points: pre-HIPEC perfusion and post-HIPEC. The cells were then concentrated. After in vitro culture, the cells underwent staining. In summary, anti-tumor marker antibodies were used to gate tumor cells. Apoptotic and viable cells were distinguished using Annexin V and Zombie dyes, respectively. Fluorescence minus one (FMO) control were implemented to establish gate boundaries, while unstained cells used as negative controls. A flow cytometer was used for data collection.</p> Results <p>This feasibility study encompassed six patients (with colorectal, colorectal, gastric, appendix, appendix, and peritoneum cancers, respectively) who underwent CRS-HIPEC between October and December 2023. Through this feasibility study, we demonstrated that evaluating the efficacy of HIPEC drug on pre- and post-HIPEC samples is achievable. The data indicated an increase in apoptotic cells by 30.6, 13.2, 12.8, 66.1, 3.9, and 8.1%, following HIPEC treatment with MMC, MMC, MMC &amp; Cisplatin, Cisplatin, MMC, and Carboplatin, respectively.</p> Conclusion <p>This feasibility study offers initial insights into the capability of a flow cytometry approach to identify and differentiate viable tumor cells from apoptotic and necrotic cells in samples obtained from HIPEC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Feasibility study of chemotherapeutic efficacy assessment in hyperthermic intraperitoneal chemotherapy (HIPEC)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Ahmed H. Mekkawy,
  • Md Khalilur Rahman,
  • Mohammad Breakeit,
  • Krishna Pillai,
  • Samina Badar,
  • Javed Akhter,
  • Michelle Dietz,
  • Shoma Barat,
  • Sarah J. Valle,
  • David L. Morris

摘要

Purpose

CRS-HIPEC serves as the primary treatment for peritoneal cancers. Although CRS-HIPEC frequently yields positive outcomes, some patients may experience a swift recurrence of cancer. Consequently, a technique to detect any remaining viable tumor cells post-treatment would be advantageous. We propose to explore the feasibility of employing flow cytometry to differentiate viable tumor cells following CRS-HIPEC treatment.

Patients and methods

During the CRS-HIPEC procedure, peritoneal fluid was collected at two distinct time points: pre-HIPEC perfusion and post-HIPEC. The cells were then concentrated. After in vitro culture, the cells underwent staining. In summary, anti-tumor marker antibodies were used to gate tumor cells. Apoptotic and viable cells were distinguished using Annexin V and Zombie dyes, respectively. Fluorescence minus one (FMO) control were implemented to establish gate boundaries, while unstained cells used as negative controls. A flow cytometer was used for data collection.

Results

This feasibility study encompassed six patients (with colorectal, colorectal, gastric, appendix, appendix, and peritoneum cancers, respectively) who underwent CRS-HIPEC between October and December 2023. Through this feasibility study, we demonstrated that evaluating the efficacy of HIPEC drug on pre- and post-HIPEC samples is achievable. The data indicated an increase in apoptotic cells by 30.6, 13.2, 12.8, 66.1, 3.9, and 8.1%, following HIPEC treatment with MMC, MMC, MMC & Cisplatin, Cisplatin, MMC, and Carboplatin, respectively.

Conclusion

This feasibility study offers initial insights into the capability of a flow cytometry approach to identify and differentiate viable tumor cells from apoptotic and necrotic cells in samples obtained from HIPEC patients.